No clear evidence of survival benefit has been definitely shown by chemotherapy in advanced non-small-cell lung cancer. We evaluated in a randomized trial the activity of the new drug lonidamine (up to 1050 mg/day) versus MVP (mitomycin C, 10 mg/m2, vinblastine, 5 mg/m2, cisplatin, 100 mg/m2). The preliminary findings on 25 patients showed that lonidamine can be easily administered at these dose ranges, and main toxicity was represented by myalgia and testicular pain. Tolerance to combination chemotherapy (MVP) was superimposable to our prior experience. Responses were recorded in both arms, and no survival difference was apparent. The study is in progress.
Get full access to this article
View all access options for this article.
References
1.
BakowskiM.T., CrouchJ.C.: Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat. Rev., 10: 159–172, 1983.
2.
BandP.R., MauronJ., PritchardK., StewartD., CoppinC.M., WilsonK., EisenhauerA.: Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat. Rep., 70: 1305–1310, 1986.
3.
FloridiA., PaggiM.G., D'AtriS., De MartinoC., MercanteM.L., SilvestriniB., CaputoA.: Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res., 41: 4661–4666, 1981.
4.
Gallo CurcioC., SalvatiF., RinaldiM., VenturoI., TonachellaR., TropeaF., Ambesi ImpiombatoF., PutilliA., Cru-cianiA.R., De GregorioM., CiottoliG.B.: Chemo-radio-therapy + lonidamine (L) in non-small cell lung cancer - limited disease. Proc. ASCO, 6: 169, n. 667, 1987.
5.
GiacconeG., BagatellaM., DonadioM., BonardiG.M., Te-storeF., FerratiP., CiuffredaL., CalciatiA.: Mitomycin C, vinblastine and cisplatin: an active regimen for non-small cell lung cancer. Br. J. Cancer, 56: 475–478, 1987.
6.
GrallaR.J., CasperE.S., KelsenD.P., BraunD., DukemanM.E., MartiniN., YoungC.W., GolbeyR.B.: Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann. Intern. Med., 95: 414–420, 1981.
7.
GrallaR.J., KrisM.G., BurkeM.T., KelsenD.P., HeelanR.: The influence of the addition of mitomycin (M) to vindesine (V) plus cisplatin (P) in a random-assignment trial in 120 patients with non-small cell lung cancer (NSCLC). Proc. ASCO, 5: 182, 1986.
8.
KaplanE., MeierP.: Nonparametric estimation from incomplete observations. J. Am. Statist. Assoc., 53: 457–481, 1958.
9.
KokronO., MacaS., ScheinerW., De GregorioN., CiottoliG.B.: Phase II study of lonidamine in inoperable non-small cell lung cancer. Oncology, 41: 84–86, 1984.
10.
KokronO., MacaS., ScheinerW.: Lonidamine in non-small cell lung cancer. Phase II study. « Screening in Oncologia », Siena, 13-16 Oct., n. 209, 1987.
11.
LongevalE., KlasterskyJ.: Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma: a study by the EORTC lung Cancer Working Party (Belgium). Cancer, 50: 2751–2756, 1982.
12.
MantelN.: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer. Chemother. Rep., 50: 163–170, 1966.
13.
MulshineJ.L., GlatsteinE., RuckdeshelJ.C.: Treatment of non-small cell lung cancer. J. Clin. Oncol., 4: 1704–1715, 1986.
14.
MurrayN., BandP.: Phase II study of lonidamine in patients with small cell carcinoma of the lung. Cancer. Treat. Rep., 71: 1283–1284, 1987.
15.
RappE., PaterJ., WilliamA., CormierY., MurrayN., EvansW., HodsonI., ClarkD., FeldR., ArnoldP., HyoubJ., WilsonK., LatreilleJ., WierzhickiR., HillD.P.: A comparison of best supportive care to two regimens of combination chemotherapy in the management of non-small cell lung cancer (NSCLC). A report of a Canadian multicentre trial. Proc. ASCO, pag. 168, n. 662, 1987.
16.
RuckdeschelJ.C., FinkelsteinD.M., EttingerD.S., CreechR.H., MasonB.A., JossR.A., VoglS.: A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J. Clin. Oncol., 4: 14–22, 1986.
17.
ScagliottiG.V.: Lonidamina: studio di fase II nel carcinoma polmonare non a piccole cellule in stadio avanzato non pretrattato. Proc. « Screening in Oncologia », Siena, 13-16 Oct., n. 20, 1987.
18.
SchulmanP., BudmanD.R., WeiselbergL., VinciguerraV., DegnanJ.T.: Phase II trial of mitomycin, vinblastine, and cisplatin (MVP) in non-small cell bronchogenic carcinoma. Cancer Treat. Rep., 67: 943–945, 1983.
19.
SilvestriniB.: Basic and applied research in the study of indazole carboxylic acids. Chemotherapy, 27 (suppl. 2): 9–18, 1981.
20.
W.H.O.Handbook for reporting results of cancer treatment. W.H.O. offset Publ. no. 48, Geneva, W.H.O., 1979.
21.
WoodsR.L., LeviJ.A., PageJ., RaghavanD., ByrneM., FoxR., Stuart-HarrisR.: Non-small cell lung cancer: a randomized comparison of chemotherapy with no chemotherapy. Proc. ASCO, 4: 177, 1985.
